Start with the decision
Define whether the purpose is exposure rescue, stable supply, route-specific performance, IP protection, regulatory control, or root-cause investigation.
Choose the solid-form path that matches the risk, not the buzzword
Polymorphs, salts, cocrystals, hydrates, solvates, amorphous materials, and ASDs are related solid-form strategies, but they are not interchangeable. Each has a different formation mechanism, control strategy, regulatory implication, and development consequence.
The comparison should begin with the decision: exposure rescue, stable supply, route-specific performance, IP protection, regulatory control, or manufacturing recovery.
Solid-form category comparison
The same API can present different development behavior depending on packing, proton transfer, coformer interactions, water or solvent incorporation, particle habit, defects, or long-range order.
| Category | Definition | Development consequence | What to check |
|---|---|---|---|
| Polymorph | Different crystalline packing or conformation of the same chemical entity. | May alter solubility, dissolution, stability, particle habit, compressibility, and process robustness. | PXRD, DSC, Raman/IR, ssNMR, microscopy, slurry conversion, thermodynamic ranking. |
| Salt | Proton transfer produces an ionic solid with a counterion. | Can improve crystallinity or solubility, but may disproportionate or show its own polymorphism. | Counterion acceptability, delta pKa, hygroscopicity, disproportionation, salt polymorphism. |
| Cocrystal | API and coformer occupy the same lattice through nonionic/noncovalent interactions. | Useful when salts fail or API is non-ionizable; can tune properties and support IP. | Coformer selection, salt/cocrystal classification, form confirmation, stability, dissociation, product relevance. |
| Hydrate / solvate | Water or solvent is present in the lattice or crystal environment. | Can emerge during humidity exposure, slurries, wet granulation, drying, storage, or solvent processing. | DVS, TGA, Karl Fischer, PXRD/Raman/IR before and after humidity or solvent stress. |
| Amorphous / ASD | No long-range crystal order; drug may be dispersed in a polymer. | Can raise apparent solubility but must be protected from recrystallization. | PXRD, DSC/Tg, DVS, Raman/ssNMR, stability, dissolution, and residual-solid analysis. |
Decision signals and recommended strategy
A comparison guide is most useful when it maps a development signal to the solid-form question and the output needed for action.
| Development signal | Solid-form question | Actionable output |
|---|---|---|
| Low solubility or weak exposure | Is the limitation molecular, solid-form, or formulation-state driven? | Rank polymorph, salt, cocrystal, and ASD options with residual-solid analysis. |
| PK or dissolution variability | Are retained lots different in form, hydration, solvation, crystallinity, particle habit, or amorphous content? | Create a form-linked root-cause conclusion and lot-history assessment. |
| cGMP or IND commitment | Can the selected form be produced, held, stressed, and monitored under realistic conditions? | Build thermodynamic ranking, stress data, and release/stability method rationale. |
| IP or lifecycle objective | What is unexpected, reproducible, useful, and distinguishable versus prior art? | Align claim-support data to property advantage and product strategy. |
Operating principles for solid-form comparisons
Use these principles before selecting a screen or comparing property data.
Do not overinterpret the first attractive lot
Rapidly isolated, kinetically trapped, mixed, hydrated, solvated, or partially amorphous material may show attractive apparent performance that does not survive scale-up.
Scale and characterize unique forms before property comparison
A one-vial hit is not yet a developable form. Confirm identity, reproducibility, and stress behavior before selecting it.
Make the evidence portable
Retained lots, method specificity, stress history, property data, and negative results should survive diligence, CMC review, and patent review.
Related solid-form pages
Polymorphism
Use this page when the comparison points to a focused solid-form development path.
Pharmaceutical Salts
Use this page when the comparison points to a focused solid-form development path.
Cocrystals
Use this page when the comparison points to a focused solid-form development path.
Amorphous Material Development
Use this page when the comparison points to a focused solid-form development path.
Crystallization Method Development
Use this page when the comparison points to a focused solid-form development path.
Habit and Morphology Engineering
Use this page when the comparison points to a focused solid-form development path.
Patent Strength Assessment
Use this page when the comparison points to a focused solid-form development path.
Manufacturing Troubleshooting
Use this page when the comparison points to a focused solid-form development path.
Common Questions
How should I choose between polymorph, salt, cocrystal, and ASD work?
Start with the development decision and the molecule. Ionizable APIs may justify salt work; non-ionizable APIs or salt failures may justify cocrystals; persistent solubility limits may justify ASD feasibility; all choices still require polymorph, hydrate, solvate, and stability awareness.
Why is experiment count not enough?
A large screen can over-sample easy crystallizations and under-sample the pathway needed to reveal a relevant form. Scope should deliberately include kinetic, thermodynamic, process-relevant, and stress conditions.
What data should carry forward?
Carry material history, form identity, comparative properties, stress history, method specificity, and negative results. These data support development decisions, control strategy, and IP review.
Can computational prediction replace experimental work?
No. Computational crystal structure prediction can guide laboratory search, but solvent effects, kinetic accessibility, conformational flexibility, and false positives mean experimental evidence is still required.
When should multiple solid-form strategies be evaluated in parallel?
Parallel evaluation can be appropriate when ionization, solubility, stability, manufacturability, or intellectual-property constraints make it unclear whether a polymorph, salt, cocrystal, hydrate, solvate, amorphous form, or ASD route will provide the best development option.
Talk to a Triclinic Labs scientist
Send the project objective, molecule constraints, current data, material history, and decision deadline so the comparison can be converted into a fit-for-purpose study plan.
